The complex shape of respiratory syncytial virus is one hurdle limiting the development of treatments for an infection that leads to hospitalization or worse for hundreds of thousands of people in the ...

What’s the RSV Timeline? Respiratory syncytial virus (RSV) is a common respiratory virus. Most people have it before age 2, but older kids and adults also get it. RSV symptoms in adults usually go ...

Respiratory syncytial virus (RSV) is a respiratory infection that has similar symptoms as a cold. But it can be serious for expectant parents who are more at risk for complications from the virus. You ...

Respiratory syncytial virus activity is still high in parts of the country amid an unusually late season. Here's where rates ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Every fall and winter, a familiar set of illnesses makes ...

Although RSV is a frequent cause of acute respiratory infections (ARIs), an estimation of its incidence has proven challenging due to a lack of routine testing, overlapping clinical presentations with ...

As cold and flu season ramps up, the most vulnerable among us need extra protection. Infants are among the most susceptible to respiratory complications from respiratory syncytial virus, or RSV. While ...

While monoclonal antibodies have been approved to treat respiratory syncytial virus (RSV) in infants and young children in Germany, the German regulatory body for vaccinations—the German National ...

If your patient is pregnant or older than 60 years and due for a respiratory syncytial virus (RSV) shot, now’s the time to act. A major new review highlighted the vaccine’s impact and safety, ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants. The US Food and Drug Administration ...

SARS-CoV-2 infection was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022-2023 respiratory illness season, while differences were less ...

On Friday, the U.S. Food and Drug Administration (FDA) expanded the approved age indication for GSK plc’s GSK respiratory ...